ANP inhibits cardiac hypertrophy in heart failure as well as fibrosis.[1] Fibrosis is inhibited by preventing fibroblasts from entering heart tissue and replicating, as well as decreasing inflammation.[1] ANP prevents hypertrophy by inhibiting calcium influx that is caused by norepinephrine.[1]
A specific ANP precursor called mid-regional pro-atrial natriuretic peptide (MRproANP) is a highly sensitive biomarker in heart failure.[2] MRproANP levels below 120 pmol/L can be used to effectively rule out acute heart failure.[2]
- ^ a b c Fu, Shihui; Ping, Ping; Wang, Fengqi; Luo, Leiming (2018-01-12). "Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure". Journal of Biological Engineering. 12 (1). doi:10.1186/s13036-017-0093-0. ISSN 1754-1611. PMC 5766980. PMID 29344085.
{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link) - ^ a b Roberts, Emmert; Ludman, Andrew J.; Dworzynski, Katharina; Al-Mohammad, Abdallah; Cowie, Martin R.; McMurray, John J. V.; Mant, Jonathan (2015-03-04). "The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting". BMJ. 350: h910. doi:10.1136/bmj.h910. ISSN 1756-1833. PMC 4353288. PMID 25740799.
{{cite journal}}: CS1 maint: PMC format (link)